Evidence map›Paper›PMID 42454409›Full record

ArticleHLA2026

Standard Single Antigen HLA Luminex Panels Predict Most, but Not All, Antibody Reactivity Against Alleles in Extended Panels.

Gerard J Chu, Rachel L Cassar, Petrina Guthrie, Anne Taverniti, David Quach, Louise Goddard, Shane Kelly, Federico Gutierrez, Lucy C Sullivan, Robert P Carroll

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gerard J ChuNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9033-4554
Rachel L CassarNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Petrina GuthrieNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Anne TavernitiNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
David QuachNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Louise GoddardNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Shane KellyNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Federico GutierrezNew South Wales Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Lucy C SullivanSouth Australia Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.
Robert P CarrollSouth Australia Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current Luminex platforms cannot represent the totality of polymorphism in human HLA. Although supplemental, extended panels are available, they are not universally applied and their diagnostic value is uncertain. It is unclear whether standard bead kits can accurately predict the reactivity seen in extended panels. This study investigated, when using the standard panel alone, whether a closest related bead strategy or an eplet pattern strategy might predict reactivity seen in an extended panel kit (Explex). In the closest related bead strategy, each bead in the extended panel was compared to a standard kit bead in the same serotype and/or had the fewest amino acid differences. Using the closest bead method the standard bead panel predicts reactivity for the majority of beads in the Explex panel (30/54 for Class I and 16/24 for Class II). In the eplet pattern strategy, the reactivity of beads in the Explex panel was predicted from proposed eplet assignment of the standard panel. This strategy showed modest accuracy for predicting positive Explex beads, with greater accuracy for Class II (25/26) compared to Class I (49/62). This strategy had similar accuracy for highly sensitised cohorts (19/22 for Class II, and 27/32 for Class I) when patterns of eplet reactivity could be identified. We found that closely-related beads and eplet patterns (when identifiable) can predict positive reactivity in unrepresented alleles with moderate success. However, we detail several exceptions where additional panel testing was found to be helpful. Our findings support selective use, rather than universal application of extended panels in our local population.

Indexed as

AllelesHistocompatibility TestingHLA AntigensIsoantibodiesHumansMicrospheresHLA AntigensIsoantibodiescrossmatchExplexLuminexsupplementaltransplantation

Identifiers

PMID42454409
PMCPMC13370519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.